Literature DB >> 15472862

Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.

F Bani-Sadr1, P Palmer, C Scieux, J M Molina.   

Abstract

We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir. The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15472862     DOI： 10.1086/424012

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Management of HIV/HBV coinfection.

Authors:  Andy O Miller
Journal:  MedGenMed       Date:  2006-02-07

Review 2.  Emerging drugs for hepatitis B.

Authors:  Fabien Zoulim
Journal:  Expert Opin Emerg Drugs       Date:  2007-05       Impact factor: 4.191

3.  Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.

Authors:  Rong-Nan Chien
Journal:  Hepatol Int       Date:  2008-04-10       Impact factor: 6.047

4.  Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda.

Authors:  Ponsiano Ocama; Emmanuel Seremba; Betty Apica; Kenneth Opio
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

5.  New approaches in the management of chronic hepatitis B: role of tenofovir.

Authors:  Jurriën Gp Reijnders; Harry LA Janssen
Journal:  Infect Drug Resist       Date:  2009-04-24       Impact factor: 4.003

6.  In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.

Authors:  Farnaz Minooei; Joel R Fried; Joshua L Fuqua; Kenneth E Palmer; Jill M Steinbach-Rankins
Journal:  Int J Nanomedicine       Date:  2021-02-15

Review 7.  Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.

Authors:  Huw Price; David Dunn; Deenan Pillay; Firouze Bani-Sadr; Theodora de Vries-Sluijs; Mamta K Jain; Noriyoshi Kuzushita; Stefan Mauss; Marina Núñez; Reto Nüesch; Marion Peters; Thomas Reiberger; Christoph Stephan; Lionel Tan; Richard Gilson
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.